Notes
J ournal of Natural Products, 1996, Vol. 59, No. 8 799
Ch a r t 1
Ta ble 1. 13C-NMR Spectral Data of Compound 3 in CD3OD
jashemsloside E decaacetate (3b) (1.3 mg). 3a : amor-
phous powder; H NMR (CDCl3) δ 1.03 (3H, d, J ) 7.0
1
carbon
C-1
C-3
C-4
C-5
C-6
C-7
C-8
C-9
C-10
C-11
OMe
C-1′, C-1′′′
C-2′, C-2′′′
C-3′, C-3′′′
C-4′, C-4′′′
C-5′, C-5′′′
C-6′, C-6′′′
δc
carbon
δc
Hz, H3-10), 1.35 (3H, s, H3-10′′), 1.68 (2H, m, H2-5′′),
1.80 (3H, d, J ) 1.0 Hz, H3-9′′), 1.85 (1H, ddd, J ) 15.5,
8.5, 5.0 Hz, H-6), 1.96 (1H, m, H-9), 1.91, 1.997, 2.004,
2.02, 2.03, 2.04, 2.10, 2.13, 2.15 (27H, each s, 9 × Ac),
2.20 (2H, m, H2-4′′), 2.24 (1H, m, H-8), 2.28 (1H, ddd, J
) 15.5, 8.5, 1.5 Hz, H-6), 3.01 (1H, br q, J ) 8.5 Hz,
H-5), 3.51 (1H, dd, J ) 11.0, 7.0 Hz, H-6′′′), 3.60 (1H,
ddd, J ) 9.5, 7.0, 2.0 Hz, H-5′′′), 3.69 (1H, dd, J ) 11.0,
2.0 Hz, H-6′′′), 3.69 (3H, s, COOMe), 3.75 (1H, ddd, J )
9.5, 4.5, 2.0 Hz, H-5′), 3.89 (1H, d, J ) 10.0 Hz, H-4′′′′),
3.97 (1H, d, J ) 10.0 Hz, H-4′′′′), 4.14 (1H, dd, J ) 12.0,
2.0 Hz, H-6′), 4.22 (1H, d, J ) 11.5 Hz, H-5′′′′), 4.33 (1H,
dd, J ) 12.0, 4.5 Hz, H-6′), 4.37 (1H, d, J ) 11.5 Hz,
H-5′′′′), 4.58 (1H, d, J ) 8.0 Hz, H-1′′′), 4.87 (1H, d, J )
8.0 Hz, H-1′), 4.91 (1H, t, J ) 9.5 Hz, H-4′′′), 4.95 (1H,
d, J ) 1.5 Hz, H-2′′′′), 4.98 (1H, dd, J ) 9.5, 8.0 Hz,
H-2′′′), 5.00 (1H, dd, J ) 9.5, 8.0 Hz, H-2′), 5.09 (1H, d,
J ) 1.5 Hz, H-1′′′′), 5.11 (1H, t, J ) 9.5 Hz, H-4′), 5.18
(1H, br t, J ) 5.0 Hz, H-7), 5.18 (1H, t, J ) 9.5 Hz,
H-3′′′), 5.23 (1H, t, J ) 9.5 Hz, H-3′), 5.24 (1H, dd, J )
17.5, 1.0 Hz, H-8′′), 5.26 (1H, d, J ) 2.5 Hz, H-1), 5.30
(1H, dd, J ) 11.0, 1.0 Hz, H-8′′), 5.72 (1H, dd, J ) 17.5,
11.0 Hz, H-7′′), 6.66 (1H, tq, J ) 7.5, 1.0 Hz, H-3′′), 7.26
(1H, br s, H-3); SIMS m/z [M + Na]+ 1251, 331, 217,
193; HRSIMS m/z [M + Na]+ 1251.4324 (calcd for
C56H76O30Na, 1251.4322). 3b: amorphous powder; 1H-
NMR (CDCl3) δ 1.03 (3H, d, J ) 7.0 Hz, H3-10), 1.36
(3H, s, H3-10′′), 1.68 (2H, m, H2-5′′), 1.80 (3H, d, J )
1.0 Hz, H3-9′′), 1.85 (1H, ddd, J ) 15.5, 8.5, 5.0 Hz, H-6),
1.95 (1H, m, H-9), 1.91, 1.996, 2.004, 2.02, 2.029, 2.032,
2.04, 2.09, 2.10, 2.12 (30H, each s, 10 × Ac), 2.18 (2H,
m, H2-4′′), 2.23 (1H, m, H-8), 2.27 (1H, ddd, J ) 15.5,
8.5, 1.5 Hz, H-6), 3.01 (1H, br q, J ) 8.5 Hz, H-5), 3.54
(1H, dd, J ) 11.0, 7.5 Hz, H-6′′′), 3.60 (1H, ddd, J )
9.5, 7.5, 2.0 Hz, H-5′′′), 3.67 (1H, dd, J ) 11.0, 2.0 Hz,
H-6′′′), 3.69 (3H, s, COOMe), 3.75 (1H, ddd, J ) 9.5, 5.0,
2.5 Hz, H-5′), 4.15 (1H, dd, J ) 12.5, 2.5 Hz, H-6′), 4.15
(1H, d, J ) 10.5 Hz, H-4′′′′), 4.22 (1H, d, J ) 10.5 Hz,
H-4′′′′), 4.33 (1H, dd, J ) 12.5, 5.0 Hz, H-6′), 4.52 (1H,
97.5
152.6
113.4
32.6
C-1′′
C-2′′
C-3′′
C-4′′
C-5′′
C-6′′
C-7′′
C-8′′
C-9′′
C-10′′
C-1′′′′
C-2′′′′
C-3′′′′
C-4′′′′
C-5′′′′
169.4
128.9
144.4
24.5
41.2
81.1
144.2
116.1
12.6
40.5
78.8a
41.1
47.3
13.8
169.4
51.8
23.7
111.1
78.2a
80.6
75.1
65.8
100.2
74.8
99.6
75.3
78.5a
71.9b
76.6
62.9
78.1a
71.7b
78.3a
62.8
a,b
Values with the same superscript are interchangeable.
3.17 (1H, dd, J ) 9.5, 8.0 Hz, H-2′′′), 3.21 (1H, dd, J )
9.5, 8.0 Hz, H-2′), 3.25 (1H, t, J ) 9.5 Hz, H-4′′′), 3.26
(1H, t, J ) 9.5 Hz, H-4′), 3.31 (1H, m, H-5′′′ or H-5′),
3.32 (1H, t, J ) 9.5 Hz, H-3′′′), 3.33 (1H, m, H-5′ or
H-5′′′), 3.38 (1H, t, J ) 9.5 Hz, H-3′), 3.54 (1H, dd, J )
11.5, 6.5 Hz, H-6′′′), 3.58 (2H, s, H2-5′′′′), 3.67 (1H, dd,
J ) 11.5, 5.5 Hz, H-6′), 3.69 (3H, s, COOMe), 3.76 (1H,
d, J ) 9.5 Hz, H-4′′′′), 3.87 (1H, d, J ) 2.5 Hz, H-2′′′′),
3.90 (1H, dd, J ) 11.5, 1.5 Hz, H-6′), 3.94 (1H, dd, J )
11.5, 2.0 Hz, H-6′′′), 3.96 (1H, d, J ) 9.5 Hz, H-4′′′′),
4.36 (1H, d, J ) 8.0 Hz, H-1′′′), 4.67 (1H, d, J ) 8.0 Hz,
H-1′), 4.97 (1H, d, J ) 2.5 Hz, H-1′′′′), 5.18 (1H, td, J )
5.0, 1.5 Hz, H-7), 5.23 (1H, dd, J ) 11.0, 1.0 Hz, H-8′′),
5.30 (1H, dd, J ) 17.5, 1.0 Hz, H-8′′), 5.31 (1H, d, J )
4.5 Hz, H-1), 5.94 (1H, dd, J ) 17.5, 11.0 Hz, H-7′′), 6.78
(1H, tq, J ) 7.5, 1.0 Hz, H-3′′), 7.43 (1H, d, J ) 1.5 Hz,
H-3); 13C-NMR data, see Table 1; HRSIMS m/z [M +
Na]+ 873.3371 (calcd for C38H58O21Na, 873.3365).
Acetyla tion of 3. J ashemsloside E (3) (5.1 mg) was
treated with Ac2O and pyridine (each 0.3 mL) at room
temperature for 2 h, and the product (8.6 mg) was
purified by preparative TLC with CHCl3-MeOH (9:1)
to afford jashemsloside E nonaacetate (3a ) (4.4 mg) and